RCUS Q1 2019 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+40.0% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$19M-1072.7% margin

Net Income

-$18M-1009.7% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+12.0%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$259M

Total Liabilities

$37M

Stockholders' Equity

$222M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+40.0%
Gross Profit	$2M	$1M	+40.0%
Operating Income	-$19M	-$13M	-40.8%
Net Income	-$18M	-$13M	-36.4%